-
Subject Areas on Research
-
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
-
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
-
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.
-
A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression.
-
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
-
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
-
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
-
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
-
A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).
-
A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells.
-
AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions.
-
Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling.
-
Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.
-
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
-
Antibody-targeted photodynamic therapy.
-
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.
-
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
-
Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer.
-
Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy.
-
Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.
-
Belatacept: is there BENEFIT for liver transplantation too?
-
CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model.
-
CTLA-4-Mediated inhibition of early events of T cell proliferation.
-
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
-
CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8.
-
CTLA4Ig: bridging the basic immunology with clinical application.
-
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.
-
Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy.
-
Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation.
-
Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection.
-
Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice.
-
Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity.
-
Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
-
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
-
High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.
-
High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
-
IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses.
-
Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis.
-
Immune status assay (ISA): a noninvasive procedure for studying allograft rejection.
-
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
-
In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
-
Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand.
-
Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
-
Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.
-
LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function.
-
Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
-
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
-
Molecular basis of T cell inactivation by CTLA-4.
-
Monoclonal antibodies for brain tumour treatment.
-
Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma.
-
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
-
New agents and regimens for diffuse large B cell lymphoma.
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
-
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
-
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.
-
Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
-
Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
-
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
-
Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.
-
Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
-
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
-
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
-
Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
-
Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
-
Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.
-
Role of interleukin 12 and costimulators in T cell anergy in vivo.
-
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
-
Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
-
Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.
-
The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation.
-
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis.
-
Three-dimensional molecular imaging with photothermal optical coherence tomography.
-
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.